Business
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 - ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, tod
About this update from Theriva Biologics, Inc.
[{"type":"image","alt":"Theriva Biologics, Inc.","displaySize":"","headline":null,"caption":"Theriva Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NwCW1pyw7ahIW1qecrDFNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a","width":300,"height":102}},"lazy":false},{"type":"text","content":"- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -","length":128,"tagName":"p"},{"type":"text","content":"- Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 -","length":140,"tagName":"p"},{"type":"text","content":"ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":336,"tagName":"p"},{"type":"text","content":"“We have started 2025 with outstanding clinical progress,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “The VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients achieved its primary survival and safety endpoints, highlighting the potential therapeutic benefits of our oncolytic virus platform. We are working to scale up manufacturing and finalize the design of a Phase 3 trial of VCN-01 with gemcitabine/nab-paclitaxel which if successful, may allow us to deliver this innovative treatment option to patients suffering this fatal disease.”","length":674,"tagName":"p"},{"type":"text","content":"Recent Highlights and Anticipated Milestones","length":44,"tagName":"p"},{"type":"text","content":"VCN-01","length":6,"tagName":"p"},{"type":"text","content":"Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC):","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"As recently announced, mPDAC pat...